First-year progress in MD Anderson’s Moon Shots Program

submitted by: mdanderson
The University of Texas MD Anderson Cancer Center in September 2012 announced its Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths. The program initially targets acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS); chronic lymphocytic leukemia (CLL); lung cancer; melanoma; prostate cancer; and triple-negative breast and high-grade serious ovarian cancers....

AML and MDS Moon Shot Annual Report 2013

submitted by: mdanderson
The University of Texas MD Anderson Cancer Center in September 2012 launched its Moon Shots Program, an ambitious and comprehensive action plan to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths. Initial moon shot cancers are breast and ovarian; acute myeloid leukemia and myelodysplastic syndromes; chronic lymphocytic leukemia; lung; melanoma and prostate cancer. Guillermo Garcia-Manero, M.D., professor in MD Anderson's...

Acute myeloid leukemia (AML) - a life threatening cancer

submitted by: mdanderson

Acute myeloid leukemia (AML) occurs when too many immature blood cells are produced by the bone marrow. Anemia, infection and bleeding may result and become life threatening. Guillermo Garcia-Manero, M.D., professor in Leukemia at MD Anderson Cancer Center, explains the symptoms, diagnosis and treatment of Acute myeloid leukemia.

Myelodysplastic Syndromes—Many New Drugs, Little Therapeutic Progress

submitted by: mcgheekkm

Dr. Ayalew Tefferi, professor of Hematology and Medicine at Mayo Clinic, discusses his article entitled "Myelodysplastic Syndromes: Many New Drugs, Little Therapeutic Progress, which appears in the November 2010 issue of Mayo Clinic Proceedings (Available at: http://tinyurl.com/32fzgtm).